지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2016.1
- 수록면
- 1,177 - 1,186 (10page)
이용수
초록· 키워드
오류제보하기
Purpose REVEL demonstrated improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) with docetaxel+ramucirumab versus docetaxel+placebo in 1,253 intent-to-treat (ITT) stage IV non-small cell lung cancer patients with disease progression following platinum-based chemotherapy. Results from the East Asian subgroup analysis are reported.
Materials and Methods Subgroup analyses were performed in the East Asian ITT population (n=89). Kaplan-Meier analysis and Cox proportional hazards regression were performed for OS and PFS, and the Cochran-Mantel-Haenszel test was performed for response rate.
Results In docetaxel+ramucirumab (n=43) versus docetaxel+placebo (n=46), median OS was 15.44 months versus 10.17 months (hazard ratio [HR], 0.762; 95% confidence interval [CI], 0.444 to 1.307), median PFS was 4.88 months versus 2.79 months (HR, 0.658; 95% CI, 0.408 to 1.060), and ORR was 25.6% (95% CI, 13.5 to 41.2) versus 8.7% (95% CI, 2.4 to 20.8).
Due to increased incidence of neutropenia and febrile neutropenia in East Asian patients, starting dose of docetaxel was reduced for newly enrolled East Asian patients (75 to 60 mg/m2, n=24). In docetaxel+ramucirumab versus docetaxel+placebo, incidence of neutropenia was 84.4% versus 72.7% (75 mg/m2) and 54.5% versus 38.5% (60 mg/m2). Incidence of febrile neutropenia was 43.8% versus 12.1% (75 mg/m2) and 0% versus 7.7% (60 mg/m2).
Conclusion Results of this subgroup analysis showed a trend favoring ramucirumab+docetaxel for median OS, PFS, and improved ORR in East Asian patients, consistent with ITT population results. Reduction of starting dose of docetaxel in East Asian patients was associated with improved safety.
목차
등록된 정보가 없습니다.
참고문헌 (25)
참고문헌 신청
Ferlay J / GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11
Schnabel PA / 2012 / Influence of histology and biomarkers on firstline treatment of advanced non-small cell lung cancer in routine care setting : baseline results of an observational study(FRAME) / Lung Cancer 78:263~269
Leighl NB. / 2012 / Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line / Curr Oncol 19(Suppl 1):52~58
Gerber DE / 2013 / Maintenance chemotherapy for advanced non-small-cell lung cancer : new life for an old idea / J Clin Oncol 31:1009~1020
Shepherd FA / 2000 / Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy / J Clin Oncol 18:2095~2103
Schnabel PA / 2012 / Influence of histology and biomarkers on firstline treatment of advanced non-small cell lung cancer in routine care setting : baseline results of an observational study(FRAME) / Lung Cancer 78:263~269
Leighl NB. / 2012 / Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line / Curr Oncol 19(Suppl 1):52~58
Gerber DE / 2013 / Maintenance chemotherapy for advanced non-small-cell lung cancer : new life for an old idea / J Clin Oncol 31:1009~1020
Shepherd FA / 2000 / Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy / J Clin Oncol 18:2095~2103
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study
Investigative and Clinical Urology
2020 .01
-
국내 위암 환자에게 투여되는 항암제 처방 양상 및 의료비용 분석: Ramucirumab 급여 전후 비교 중심으로
보건의료기술평가
2022 .12
-
The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma
Tuberculosis and Respiratory Diseases
2019 .01
-
Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy
Cancer Research and Treatment
2015 .01
-
Docetaxel-Aggravated Psoriasis
Annals of Dermatology
2019 .01
-
Metformin Addition to Chemotherapy in Stage IV Non-Small Cell Lung Cancer: an Open Label Randomized Controlled Study
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer
Cancer Research and Treatment
2016 .01
-
Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study
Investigative and Clinical Urology
2019 .01
-
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
Cancer Research and Treatment
2018 .01
-
Effects of combination therapy of docetaxel with selenium on the human breast cancer cell lines MDA-MB-231 and MCF-7
Annals of Surgical Treatment and Research
2015 .01
-
Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer
Cancer Research and Treatment
2018 .01
-
Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area
Cancer Research and Treatment
2018 .01
-
ABT-737 ameliorates docetaxel resistance in triple negative breast cancer cell line
Annals of Surgical Treatment and Research
2018 .11
-
Talazoparib versus Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial
Cancer Research and Treatment
2021 .10
-
A phase I dose-finding trial of hyperthermic intraperitoneal docetaxel combined with cisplatin in patients with advanced-stage ovarian cancer
Journal of Gynecologic Oncology
2024 .01
-
Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice
Yonsei Medical Journal
2023 .02
-
Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05)
Cancer Research and Treatment
2018 .01
-
Evaluation the Use of Frozen Sock to Prevent Docetaxel-Induced Peripheral Neuropathy in Breast Cancer Patients
대한외과학회 학술대회 초록집
2018 .11
-
Comparative In Vitro Toxicity Study of Docetaxel and Nanoxel, a Docetaxel-Loaded Micellar Formulation Using Cultured and Blood Cells
Toxicological Research
2019 .04
-
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis
Cancer Research and Treatment
2017 .07
이 논문의 저자 정보
최근 본 자료
댓글(0)
0